As highlighted in an earlier Catalyst post, PhRMA is partnering with Genetic Alliance on an exciting project to enhance patient engagement in the Food and Drug Administration’s (FDA) Patient-Focused Drug Development initiative. Genetic Alliance recently launched the first pilot program, partnering with four trusted organizations serving the sickle cell community.
Most Recent Posts
A new study examines the economic impact of India’s current approach to intellectual property rights as it affects pharmaceutical products and Foreign Direct Investment (FDI). The study from Sonecon by Robert Shapiro and Aparna Mathur titled “How India Can Attract More Foreign Direct Invest Investment, Create Jobs, and Increase GDP: The Benefits of Respecting the Intellectual Property Rights of Foreig
Today, on World Cancer Day, we celebrate the remarkable progress that’s been made in the fight against a devastating disease that has touched all of us.
A groundbreaking new partnership was announced earlier today by the National Institutes of Health (NIH).
The Washington Legal Foundation recently convened an enlightening expert roundtable discussion about the impact of late 2012's decision in U.S. vs. Caronia.
What does working in a lab have in common with flying an airplane? A great deal according to the next researcher highlighted in our “I am Research, Progress, Hope” series, Dowdy Jackson, head of the Antibody Drug Conjugate (ADC) Biology group at Agensys, an affiliate of Astellas.
As of January 1, researchers are now able to submit proposals to receive access to patient level data, protocols, and clinical study reports for new medicines approved in the U.S and EU after January 1, 2014. The biopharmaceutical sector’s commitment to data sharing provides new avenues for the scientific community and patients to benefit from clinical research, while maintaining patient privacy, the integrity of national regulators, and incentives for companies to make long-term investments in biomedical research.
Dr. Robert Freeman, Professor of Pharmacy Administration (health services research) in the Department of Pharmacy Practice & Administration at the University of Maryland Eastern Shore School of Pharmacy, comments on the recently released paper from University College London School of Pharmacy on patient’s needs and intellectual property in middle income countries.
In his State of the Union, President Obama said, "A nation that goes all-in on innovation today will own the global economy tomorrow." We couldn't agree more.
Today’s featured scientist comes from Agensys, a subsidiary of Astellas, where she is working on developing a treatment or cure for different types of cancers.
The great inventor and businessman Henry Ford once said, “Whether you think you can, or think you can’t – you’re right."
When looking at an issue as important and complex as health care costs in the U.S., it’s critical that full facts, not select data, lead the discussion. Drew Armstrong’s recent article about a Hepatitis C medicine paints an incomplete picture of our health care system and further propels inaccurate information about prescription medicines.
When considering the benefits and risks of medicines, patients provide a unique perspective of unparalleled value. A deep understanding of the patient perspective on benefits and risks throughout the drug development process has the potential to significantly advance the biopharmaceutical industry’s efforts to bring to patients new medicines that extend and improve the quality of their lives.
Before the holidays, PhRMA’s General Counsel Mit Spears wrote a post in The Catalyst about the need for a new regulatory paradigm to govern how the biopharmaceutical industry communicates with healthcare professionals about the medicines that our companies research and develop.
Dr. Richard Moscicki, Deputy Center Director for Science Operations at the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), noted in his remarks at the FDA public workshop on Complex Issues in Developing Drug and Biological Products for Rare Diseases held earlier this month that more than a third of the novel drugs approved in CY13 treat rare disease.